<DOC>
	<DOCNO>NCT00004658</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate efficacy oral ribose patient complex 5'-nucleotidase syndrome receive uridine ( UR ) thymidine ( TDR ) . II . Evaluate efficacy UR/oral ribose UR/TDR . III . Evaluate efficacy oral ribose give combination UR/TDR .</brief_summary>
	<brief_title>Phase II Study Ribose , Uridine , Thymidine Complex Syndrome Involving Excessive 5'-Nucleotidase Activity</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Newly identify patient receive ribose daily 8 week . Patients improve continue therapy . If improvement reach plateau , uridine ( UR ) thymidine ( TDR ) add regimen . Patients receive benefit 8 week ribose treat UR/TDR . Patients improve 8 week combination continue therapy . Ribose add treatment regimen patient UR/TDR entry . At maximal improvement , TDR UR sequentially taper .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Complex syndrome excessive skin fibroblast 5'nucleotidase activity characterize : Recurrent infection Seizure disorder Speech impairment Attention deficit behavior problem Prior/Concurrent Therapy Concurrent uridine thymidine therapy allow Patient Characteristics Other : No pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>5'-nucleotidase syndrome</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>rare disease</keyword>
</DOC>